Recombinant Human CDH17 Protein (His Tag)

Name: Recombinant Human CDH17 Protein (His Tag)
Brand: Beta LifeScience
SKU: BLPSN-1187
Availability: InStock

Collections: Cluster of differentiation (cd) proteins, Featured cd protein molecules, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag	His
Host Species	Human
Accession	Q12864
Synonym	CDH16, HPT-1, HPT1
Background	Cadherin-17 or LI-cadherin is a member of the cadherin superfamily, genes encoding calcium-dependent, membrane-associated glycoproteins. Cadherin-17/LI-cadherin is a cadherin-like protein consisting of an extracellular region, 7 cadherin domains, and a transmembrane region but lacking the conserved cytoplasmic domain. The protein is a component of the gastrointestinal tract and pancreatic ducts, acting as an intestinal proton-dependent peptide transporter in the first step in oral absorption of many medically important peptide-based drugs. The protein may also play a role in the morphological organization of liver and intestine. Alternative splicing of the encoding gene results in multiple transcript variants. Cadherin-17/LI-cadherin preferentially interact with themselves in a homophilic manner in connecting cells. Cadherin-17 may thus contribute to the sorting of heterogeneous cell types and have a role in the morphological organization of liver and intestine. It's also involved in intestinal peptide transport. Experiments have reported the association between Cadherin-17/LI-cadherin and gastric cancer. Cadherin-17/LI-cadherin expression was detected in 63/94 of gastric adenocarcinomas in addition to intestinal metaplasia. The expression of Cadherin-17 tended to be associated with intestinal type carcinoma, and carcinomas with Cadherin-17 expression was significantly more frequent in advanced stage cases than in early stage. Cadherin-17 is also a useful immunohistochemical marker for diagnosis of adenocarcinomas of the digestive system.
Description	A DNA sequence encoding the human CDH17 (Q12864-1) extracellular domain (Met 1-Met 787) was expressed, fused with a His tag at the C-terminus.
Source	HEK293
Predicted N Terminal	Gln 23
AA Sequence	Met 1-Met 787
Molecular Weight	The recombinant human CDH17 consists of 776 a.a. and predictes a molecular mass of 87 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rh CDH17 is approximately 105-115 kDa due to glycosylation.
Purity	>88% as determined by SDS-PAGE
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity	Please contact us for detailed information
Formulation	Lyophilized from sterile PBS, pH 7.4.
Stability	The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage	For Research Use Only
Storage	Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. LI-cadherin may have a role in the morphological organization of liver and intestine. Involved in intestinal peptide transport.
Subcellular Location	Cell membrane; Single-pass type I membrane protein.
Database References	HGNC: 1756 OMIM: 603017 KEGG: hsa:1015 STRING: 9606.ENSP00000027335 UniGene: Hs.591853
Tissue Specificity	Expressed in the gastrointestinal tract and pancreatic duct. Not detected in kidney, lung, liver, brain, adrenal gland and skin.

Gene Functions References

CDH17 has a role in altering MMP-2 expression via canonical NF-kappaB signalling in human gastric cancer PMID: 29783070
Data show that alteration in beta-catenin expression, a core component of the CDH17/beta-catenin axis, in tumors affects serine peptidase inhibitor Kazal type 1 (SPINK1) serum levels in hepatocellular carcinoma (HCC) patients. PMID: 28631187
However, CDH17 expression was significantly elevated in patients with stage II and III gastric cancers compared to that in healthy controls (p= 0.023 and p= 0.037, respectively). PMID: 28453457
CDH17 and CLDN18 are useful target molecules. Their coupling can aid in the comprehensive detection and localization of gastric cancer metastases in vivo to overcome challenges associated with intratumoral heterogeneity. PMID: 27580354
CDH17 is a sensitive marker for midgut WDNETs, and the CDH17+/CDX2-/TTF1- phenotype was found to be sensitive (92%) and specific (91%) for hindgut well-differentiated neuroendocrine tumours (WDNETs). PMID: 25388236
Using a lentiviral system as a delivery mediator of RNA interference, we found that inhibition of CDH17 can lead to reduce proliferation and increase apoptosis of gastric cancer cell line MKN28 in vitro and significantly diminish their tumorigenicity in vivo. Our results of the present study suggest that CDH17 may be a promising candidate for the therapeutic targeting of gastric cancer. PMID: 27909714
In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. PMID: 28029907
These data indicate that knockdown of LIcadherin facilitates the invasion of cancer cells by degrading extracellular matrix components via activation of MMP2 and 9, and increases cancer cell adhesion and migration via altered expression of galectin3. PMID: 27035870
Fascin-1 expression, cadherin-17 expression, tumor size, and differentiation were independent risk factors for GC. PMID: 26743780
Mutations in CDH17 gene is associated with idiopathic hypereosinophilic syndrome. PMID: 26497854
Review/Meta-analysis: data reflect the role of CDH17 in tumor proliferation and metastasis among gastric cancer patients. PMID: 25834338
CDH17 is a sensitive (81%) and highly specific (100%) marker for metanephric adenoma. PMID: 25768256
RGD motif present in cadherin 17 induces integrin activation and tumor growth PMID: 25336636
Data suggest that combined tumor expression of CDH17 (cadherin-17) and SATB2 (special AT-rich sequence binding protein 2) may be used as diagnostic biomarkers in subjects with medullary carcinoma of the large intestine (colon; cecum). PMID: 24437456
Data reveal a new function for CDH17, which is to regulate alpha2beta1 integrin signaling in cell adhesion and proliferation in colon cancer cells for liver metastasis. PMID: 23604127
The SNPs of the CDH17 gene c.2216 A>C might be clinically important in the prognosis of colorectal carcinoma. PMID: 23326130
This study demonstrates that the secreted form of cadherin-17 (ectodomain) is truncated at the C-terminus. PMID: 23557862
results identify CDH17 as a biomarker of gastric carcinoma and attractive therapeutic target for this aggressive malignancy. PMID: 23554857
Cadherin-17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFkappaB signaling pathway. PMID: 23298905
LI-cadherin is a sensitive marker of intestinal metaplasia and can be helpful for early histologic diagnosis of Barrett's esophagus (BE); it is not, however, significantly different between BE with and without intestinal epithelial neoplasia. PMID: 23053896
Up-regulation of cadherin 17 is associated with epithelial ovarian cancer progression. PMID: 22810971
Report less aggressive behavior of gastric tumors after CDH17 gene knockdown. PMID: 22791949
CDH17 was positively associated with larger tumor size, deeper invasion, diffuse/mixed histotype, LVI, and LNMM, predicting a poor prognosis in pN0 gastric cancer. PMID: 22009269
LI cadherin is associated with an intestinal phenotype and an 'intestinal pathway' of carcinogenesis in intraductal papillary mucinous neoplasm. PMID: 22286087
we proposed that CDH17 may be an oncogene up-regulating invasive features of gastric cancer cells PMID: 20393816
CDH17 expression may be well preserved during the metastatic process and therefore be a useful marker for identifying colorectal adenocarcinomas in a metastatic setting with an unknown primary site PMID: 21323956
Targeting CDH17 in HCC can inhibit tumor growth and inactivate Wnt signaling pathway in concomitance with activation of tumor suppressor genes.[review] PMID: 20580775
CDX2 and LI-cadherin are sensitive markers of intestinal metaplasia with or without dysplasia in the upper gastrointestinal tract. PMID: 20444732
identified the minimal promoter region of CDH17 that is regulated by HNF1alpha and CDX2 transcriptional factors; Suppression of HNF1alpha and CDX2 expression by siRNA down-regulated expressions of CDH17 and cyclin D1 and the viability of HCC cells PMID: 20568120
Li-cadherin participates in the multiple steps of invasion and metastasis in a colorectal cancer cell line. PMID: 20204409
CDH17 maybe a positive regulator for proliferative, adhesive, and invasive behaviors of gastric cancer. PMID: 20500517
Expression of CDH17 and MUC13 was up-regulated in gastric cancer tissues. CDH17 is a promising prognostic marker for early stage gastric cancer. PMID: 20398667
Loss of LI-cadherin results in up-regulation of MTF-1 and PlGF, thereby regulating angiogenesis in intrahepatic cholangiocarcinoma PMID: 19956853
High xpression of liver-intestine cadherin and its possible interaction with galectin-3 is associated with ductal adenocarcinoma of the pancreas PMID: 12824888
tumor staging and LI-cadherin expression were found to be independent factors associated with lymph node metastasis. PMID: 15178443
LI-cadherin may have a role in lymph node metastasis and progression of human colorectal carcinoma PMID: 15279905
Aberrant alternative splicing of LI-cadherin is associated with hepatocellular carcinoma PMID: 15701831
The functional T-G haplotype of CDH17 (651 C>T and IVS6+35A>G) is a genetic susceptibility factor for the development of Hepatocellular carcinoma (HCC) in a Chinese population. PMID: 16951245
Reduced expression of liver intestine-cadherin had a significant correlation with tumoral dedifferentiation and short overall survival in colorectal cancer. PMID: 17828401
combined detection of CDH17/CDX2 co-expression may benefit us in predicting the prognosis of gastric carcinoma. PMID: 18353622
Cadherin-17 is a useful immunohistochemical marker for diagnosis of adenocarcinomas of the digestive system. PMID: 18552820
CDH17 is a novel oncogene in hepatocellular carcinoma. CDH17 is a biomarker and attractive therapeutic target for this aggressive malignancy. PMID: 19676131

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.